FeesSafety
Pluang+

FDA reschedules NeOnc's NEO212 Phase 1 meeting to Nov 23 to discuss Phase 2 trial plans for CNS cancer drug.

Market News
19 Nov 2026, 20:37 WIB
GlobeNewsWire
View Source
Bullish
FDA reschedules NeOnc's NEO212 Phase 1 meeting to Nov 23 to discuss Phase 2 trial plans for CNS cancer drug.

NeOnc Technologies announced the FDA has rescheduled its End-of-Phase 1 Type B meeting for oral NEO212 to November 23, 2026. The meeting will focus on Phase 2 study design, patient population, endpoints, dose selection, and regulatory pathways following completion of Phase 1 dose escalation. NEO212 showed promising clinical activity in Phase 1, including tumor reduction and prolonged disease control in CNS cancer patients. NeOnc plans to discuss FDA feedback and next steps in an upcoming investor webinar.

NeOnc Technologies' FDA meeting reschedule is noted alongside a broad downturn in the health sector on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 20, 2026 01:22 WIB: out of 150 priced US health stocks, 23 rose and 125 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 1.76 with a 1-day change of -4.86% and a typical hold time of 27 days, Ascendis Pharma A/S (ASND) at USD 257.48 down 4.75%, and BrightSpring Health Services Inc. (BTSG) at USD 65.12 down 4.71%.

More News

Realty Income REIT offers a 5.6% yield amid easing rate fears and steady retail tenants.

Realty Income REIT offers a 5.6% yield amid easing rate fears and steady retail tenants.

Realty Income, a real estate investment trust specializing in retail properties, currently offers a forward dividend yield of 5.6%. Despite concerns about rising interest rates and economic pressures, its strong tenant base including Walmart and Walg...

Market News
Bullish
57 minutes ago
Valvoline posts 22% Q4 sales growth, surpasses $4B annual sales with strong store expansion.

Valvoline posts 22% Q4 sales growth, surpasses $4B annual sales with strong store expansion.

Valvoline reported a 22% increase in net sales to $555 million in Q4 2026 and achieved over $4 billion in annual system-wide sales across 2,517 stores. The company marked its 20th consecutive year of same-store sales growth, driven by price adjustmen...

Company Fundamentals
Bullish
57 minutes ago
SpaceX shares drop 4% as Anthropic's IPO rally fades, revealing risks tied to a $120B contract.

SpaceX shares drop 4% as Anthropic's IPO rally fades, revealing risks tied to a $120B contract.

SpaceX stock fell 4% after Anthropic's AI company IPO initially surged but then declined, dampening the tech market rally. Anthropic, a major customer of SpaceX's AI division, has committed up to $120.5 billion for computing capacity through 2029, wi...

Market News
Bearish
59 minutes ago
Nvidia, Amazon, and Alphabet poised to benefit from Anthropic's AI IPO success.

Nvidia, Amazon, and Alphabet poised to benefit from Anthropic's AI IPO success.

Anthropic's recent IPO has generated excitement, but some investors prefer to wait for more financial data before investing directly. Nvidia, Amazon, and Alphabet stand to gain significantly from Anthropic's growth, as Nvidia supplies key AI hardware...

Market News
Bullish
1 hour ago
Bath & Body Works beats sales expectations with $1.6B Q3, launches new products, and saves $200M in costs.

Bath & Body Works beats sales expectations with $1.6B Q3, launches new products, and saves $200M in costs.

Bath & Body Works reported $1.6 billion in net sales for Q3 2026, surpassing management's guidance. The company is successfully launching new product franchises like Essentials and Everyday Luxuries, which are driving higher repeat customer purchases...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App